Trevena, Inc. (TRVN) Just Recorded A Sigfniciant Increase

May 6, 2018 - By Hazel Jackson

Trevena, Inc. (NASDAQ:TRVN) Logo

The stock of Trevena, Inc. (NASDAQ:TRVN) is a huge mover today! The stock increased 5.66% or $0.12 during the last trading session, reaching $2.24. About 1.67 million shares traded or 106.66% up from the average. Trevena, Inc. (NASDAQ:TRVN) has declined 53.76% since May 6, 2017 and is downtrending. It has underperformed by 65.31% the S&P500.
The move comes after 5 months positive chart setup for the $149.97 million company. It was reported on May, 6 by We have $2.44 PT which if reached, will make NASDAQ:TRVN worth $13.50M more.

More recent Trevena, Inc. (NASDAQ:TRVN) news were published by: which released: “Trevena (TRVN) Reports Licensing Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd for Oliceridine in China” on May 01, 2018. Also published the news titled: “Trevena Reports First Quarter 2018 Financial Results” on May 03, 2018.‘s news article titled: “Trevena up 11% premarket on oliceridine deal in China” with publication date: May 02, 2018 was also an interesting one.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has market cap of $149.97 million. The Company’s product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.